Impact of 3rd generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC): A meta-analytical approach

被引：0
|
作者：
Grossi, Francesco
Belvedere, Ornella
Defferrari, Carlotta
Rosetti, Francesco
Vinante, Orazio
Pappagallo, Giovanni
机构：
[1] Ist Nazl Ric Canc, I-16132 Genoa, Italy
[2] Univ Udine, I-33100 Udine, Italy
[3] Osped PF Calvi, Noale, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：227 / 227
页数：1
相关论文
共 50 条
  • [31] Phase I/II trial of docetaxel (D) and Carboplatin (CBDCA) as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Giannakakis, T
    Papadouris, S
    Kourousis, C
    Kalbakis, NK
    Tzianni, V
    Lidaki, E
    Androulakis, N
    Souklakos, J
    Sarra, E
    Georgoulias, V
    ANNALS OF ONCOLOGY, 1998, 9 : 94 - 94
  • [32] Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer
    Kim, SW
    Suh, C
    Lee, SD
    Kim, WS
    Kim, DS
    Kim, WD
    Lee, JS
    LUNG CANCER, 2003, 41 (02) : 221 - 226
  • [33] Nutritional status changes in patients with advanced non-small cell lung cancer receiving first-line chemotherapy
    Wei Sun
    Shunfang Liu
    Ping Peng
    Dongbo Liu
    Oncology and Translational Medicine, 2018, 4 (02) : 54 - 57
  • [34] Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer:: a phase II trial
    Laack, E
    Mende, T
    Benk, J
    Chemaissani, A
    Scholtze, J
    Lorenz, C
    Niestroy, A
    Dalhoff, K
    Müller, T
    Walter, T
    Dürk, H
    Edler, L
    Hossfeld, DK
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (05) : 583 - 590
  • [35] Oxaliplatin and docetaxel as first line chemotherapy for patients with non-small cell lung cancer (NSCLC).
    Santos, ES
    Raez, LE
    Rocha-Lima, C
    Tolba, K
    Negret, L
    Farfan, N
    Decesare, T
    Lopes, G
    Rosado, MF
    Wu, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 687S - 687S
  • [36] Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis
    Li, Dan-Ni
    Lu, Wen-Qing
    Yang, Bo-Wen
    Zhang, Ling-Yun
    Jin, Bo
    Wang, Shuo
    Che, Xiao-Fang
    Li, Ce
    Liu, Yun-Peng
    Qu, Xiu-Juan
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [37] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [38] Costs associated with neutropenia in elderly patients treated first-line for advanced non-small cell lung cancer (NSCLC)
    Stokes, M. E.
    Muehlenbein, C. E.
    Marciniak, M. D.
    Faries, D.
    Motabar, S.
    Buesching, D. P.
    Gillespie, T. W.
    Lipscomb, J.
    Knopf, K. B.
    VALUE IN HEALTH, 2008, 11 (03) : A10 - A10
  • [39] First-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) in China in the era of precision medicine
    Zhang, X.
    Zhou, Q.
    Song, Y.
    Chen, G. Y.
    Zhong, D. S.
    Yu, Z.
    Yu, P.
    Zhang, Y. P.
    Chen, J. H.
    Hu, Y.
    Feng, G. S.
    Song, X.
    Shi, Q.
    Yang, L. L.
    Zhang, P. H.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Butts, C. A.
    Bodkin, D.
    Middleman, E. L.
    Englund, C. W.
    Ellison, D.
    Alam, Y. Z.
    Pautret, V.
    Weber, M.
    Kreisman, H.
    Shepherd, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345